EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Immune checkpoint inhibitors in gynecologic oncology: Current status and perspectives

Nozomu Yanaihara iD, Ka Yu Tse, Sung Jong Lee, Ji Geun Yoo, Sarikapan Wilailak

International Journal of Gynecology & Obstetrics · 2025-09 · 171 (S1) · 166-188

DOI: 10.1002/ijgo.70280 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Gynecology & Obstetrics, online erschienen am 04.09.2025. Verfasst von Nozomu Yanaihara und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, The Jikei University School of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Genital Neoplasms, Female. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 134 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoint inhibitors (ICIs) have transformed cancer treatment by leveraging the immune system's capacity to fight gynecologic cancer. This review summarizes the current status and future perspectives of ICIs in the treatment of cervical, endometrial, and ovarian cancers and rare tumors. ICIs have demonstrated significant efficacy in tumors with high tumor mutational burden and immune markers such as PD‐L1 expression and microsatellite instability. In cervical cancer, the integration of ICIs has shown promise at various stages of treatment, including advanced and recurrent settings. In endometrial cancer, molecular classification has facilitated targeted immunotherapy strategies, with notable success in mismatch repair‐deficient (dMMR) tumors. However, challenges remain in the treatment of microsatellite stable endometrial and epithelial ovarian cancers due to their relatively low immunogenicity. Combination therapies, including ICIs with angiogenesis inhibitors, poly (ADP‐ribose) polymerase (PARP) inhibitors, or chemotherapy, are being actively investigated to improve response rates. Several phase II and case series showed promising response to ICIs in vulvar/vaginal cancer and gestational trophoblastic neoplasia, though the efficacy in genital tract melanoma is still unclear. Despite these advances, the management of immune‐related adverse events and the identification of reliable biomarkers for patient selection remain critical. ICIs are poised to redefine the therapeutic landscape of gynecologic oncology, offering hope for improved outcomes and personalized treatment strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsGenital Neoplasms, FemaleHumansFemaleOvarian NeoplasmsImmunotherapyUterine Cervical NeoplasmsEndometrial NeoplasmsMicrosatellite Instability

Stichwörter der Autor:innen

cervical cancerendometrial cancerimmune checkpoint inhibitorsovarian cancer

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, The Jikei University School of Medicine, Tokyo, Japan.
  • Department of Obstetrics and Gynaecology, The University of Hong Kong, Pokfulam, Hong Kong.
  • Department of Obstetrics and Gynecology, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Republic of Korea.
  • Department of Obstetrics and Gynecology, Daejeon St. Mary's Hospital, The Catholic University of Korea, Daejeon, Republic of Korea.
  • Department of Obstetrics and Gynecology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.

ORCID-Profile: Nozomu Yanaihara

Zitieren

APA

Yanaihara, N., Tse, K. Y., Lee, S. J., Yoo, J. G., & Wilailak, S. (2025). Immune checkpoint inhibitors in gynecologic oncology: Current status and perspectives. International Journal of Gynecology & Obstetrics, 171(S1), 166-188. https://doi.org/10.1002/ijgo.70280

Vancouver

Yanaihara N, Tse KY, Lee SJ, Yoo JG, Wilailak S. Immune checkpoint inhibitors in gynecologic oncology: Current status and perspectives. International Journal of Gynecology & Obstetrics. 2025;171(S1):166-188. doi:10.1002/ijgo.70280

BibTeX
@article{Yanaihara2025,
  author = {Yanaihara, Nozomu and Tse, Ka Yu and Lee, Sung Jong and Yoo, Ji Geun and Wilailak, Sarikapan},
  title = {Immune checkpoint inhibitors in gynecologic oncology: Current status and perspectives},
  journal = {International Journal of Gynecology & Obstetrics},
  year = {2025},
  volume = {171},
  number = {S1},
  pages = {166--188},
  doi = {10.1002/ijgo.70280}
}
Kostenlos starten →